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BG00010 is a protein in the glial cell line-derived neurotrophic factor (GDNF) family. It is a selective ligand for the GDNF family
receptor alpha-3 (GFRα3) co-receptor that normalizes cellular changes resulting from damage or disease, and potentially
alleviates neuropathic pain. The main objectives of this study were to evaluate the pharmacokinetic and safety profiles and to
determine the effects on pain of ascending doses of intravenous injections of BG00010 in patients with sciatica.
METHODS
This was a randomized, blinded, placebo-controlled multiple-dose study in subjects with sciatica. In Part I (16 patients), four IV
dose levels were examined (50, 150, 400, 800 μg kg1) and in Part II (12 patients), three dose levels were examined (400, 600 and
1200 μg kg1). Safety and efficacy assessments were used as endpoints.
RESULTS
The BG00010 concentration–time data indicated relatively low inter-patient variability and there was a dose-dependent (not
dose-proportional) increase in serum exposure from 150 to 1200 μg kg1. The effective half-life was between 40 and 60 h. The
most frequently occurring adverse events (AEs) reported by patients receiving BG00010 were headache (67–83%), feeling hot
(50–100%), and pruritus (42–67%). Most AEs were mild; no serious AEs or AEs leading to discontinuation occurred. Higher dose
regimens of BG00010 resulted in greater pain reduction than placebo or lower dose regimens, although a clear dose–response
relationship was not seen.
CONCLUSIONS
The pharmacokinetic profile of BG00010 was characterized by low intra-patient variability. These data from a small sample
suggest that BG00010 may have a benefit for patients with sciatica.© 2016 The British Pharmacological Society DOI:10.1111/bcp.12941
P. Okkerse et al.WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT
• Preclinical data from surgical and chemical nerve-injury models suggest that BG00010 attenuates pain-related behaviours and
normalizes the neurochemical status of injured small dorsal root ganglion (DRG) neurons without loss of neuronal or axonal
function or integrity.
• Along with promoting re-entry of sensory fibres into the spinal cord and re-establishing synaptic function after crush injury,
BG00010 can promote recovery of simple and complex behaviours in preclinical models.
WHAT THIS STUDY ADDS
• Current treatment for sciatica and other neuropathic pain conditions are inadequate, and these data give further support to the
concept that compounds targeting neurotrophic factor pathways such as the glial cell-derived neurotrophic factor (GDNF)
family of ligands may provide viable therapies.
• These data indicate that initial safety, pharmacokinetic profile and analgesic effects of BG00010 are promising and warrant
further evaluation in patients with neuropathic pain.Introduction
BG00010 (neublastin, artemin) is a glial cell-derived neuro-
trophic factor (GDNF) family member [1] that can act as a
survival factor for sensory and sympathetic neurons.
BG00010 is a selective ligand for the GDNF family receptor
alpha-3 (GFRα3) co-receptor. The interaction of BG00010
with GFRα3 on nociceptive sensory neurons activates down-
stream signalling to normalize damage- or disease-induced
cellular changes and potentially alleviate neuropathic pain.
GFRα3 expression is highly restricted to small dorsal root
ganglion (DRG) sensory neurons, reducing the likelihood of
unintended side effects [2].
Preclinical data from surgical and chemical nerve-injury
models demonstrate that BG00010 attenuates pain-related
behaviours and normalizes the neurochemical status of in-
jured small DRG neurons without loss of neuronal or axonal
function or integrity. Along with promoting re-entry of sen-
sory fibres into the spinal cord and re-establishing synaptic
function after crush injury, BG00010 can promote recovery
of simple and complex behaviours in preclinical models [3–5].
BG00010 is being developed as a first-in-class molecule for the
treatment of neuropathic pain.
Neuropathic pain results from lesions or disease affecting
the peripheral or central somatosensory nervous system.
Neuropathic pain is especially problematic because of its
severity, chronicity and resistance to simple analgesics.
Affecting 2–3% of the population, neuropathic pain is costly
to the healthcare system, personally devastating for patients
[6], and can substantially impair health-related quality
of life [7].
Sciatica is caused by spinal nerve root compression, often
due to lumbar disc prolapse, and is associated with back pain ra-
diating to the leg, occasionally accompanied by neurological
deficit [8]. Sciatica is common, with reported lifetime incidence
of 13–40% [9] and an annual incidence of 1–5%, peaking in
the fifth decade of life [10]. Most patients with acute sciatica re-
spond to conservative symptom management, with symptom
resolution overweeks tomonths, although some require surgical
decompression of the affected nerve root. Nevertheless, 10–40%
of patients will develop a chronic pain syndrome [11]. Common
pharmacotherapies for chronic neuropathic pain include tricy-
clic antidepressants, serotonin-norepinephrine reuptake inhibi-
tors, calcium channel α2-δ ligands, topical lidocaine, opioid2 Br J Clin Pharmacol (2016) •• ••–••agonists and capsaicin. For sciatica, epidural steroid injections
have been used for decades despite inconclusive efficacy data [9].
Treatment remains challenging, asmany patients do not experi-
ence sufficient relief [12]. A significant unmet medical need
exists for a therapeutic agent with an acceptable safety profile
to provide sustained neuropathic pain relief.
In a previous single-centre study (NCT00961766),
BG00010 was administered to 48 patients with sciatica as
single intravenous (IV; 0.3–800 μg kg1) or subcutaneous
(50 μg kg1) doses [13]. The results suggested nearly linear
pharmacokinetics (PK) over the tested dose range. The most
frequently reported adverse events (AEs) were feeling hot,
pruritus, headache and rash. In this second study of
BG00010 in humans, the main objectives were to evaluate
the PK, safety and pharmacodynamics of three IV injections
of BG00010 given as two fixed dosing schedules.Methods
Patients
Eligible patients were aged 18–85 years with a diagnosis of
unilateral sciatica, including pain radiating down the leg
following a dermatome, suggesting L4, L5 or S1 nerve root
involvement, with symptoms present for ≥3 months prior
to the screening visit, and pain rated at ≥40 mm on a
100 mm visual analogue scale (VAS) of the Dutch translation
of the Short-Form McGill Pain Questionnaire (SF-MPQ) [14]
at screening and baseline visits.
Key exclusion criteria included: history of severe pain or
signs/symptoms of peripheral neuropathy (other than that
caused by sciatica) during the 3months prior to the screening
visit; major surgery within the 3 months prior to the screen-
ing visit or planned sciatica surgery within 6 months of the
screening visit; current generalized myalgia; history of severe
allergic or anaphylactic drug-related reaction; history of
malignancy or clinically relevant allergy; and/or cardiac,
endocrine, haematologic, hepatic, immunologic, metabolic,
urologic, pulmonary, neurologic (not related to sciatica),
dermatologic, rheumatic/joint, psychiatric, renal and/or
other major disease.
Patients were allowed treatment with a selective seroto-
nin reuptake inhibitor, a serotonin noradrenaline reuptake
PK/PD of the neurotrophic factor BG00010 in patients with sciaticainhibitor, gabapentin, or a tricyclic antidepressant if doses
were stable for 4 weeks prior to the baseline visit, and
pregabalin if the dose was stable for 1 week prior to the base-
line visit. Doses of other prescription medications and/or
over-the-counter products were to have been stable for
2 weeks prior to the baseline visit. Previous participation in
a study with neurotrophic factors and participation in a study
with another investigational drug or approved therapy for in-
vestigational use within 3 months prior to the baseline visit
was not allowed.Study design and treatment
This was a single-centre, randomized, blinded, placebo-
controlled, serial-cohort, multiple-dose ascending study
that examined two dose schedules (ClinicalTrials.gov
NCT01405833). The study was approved by the Medical
Ethics Committee (BEBO Foundation, Assen, The Nether-
lands) and all patients gave written informed consent.
‘BG00010’ is specific for the isoform of the protein used
in this study (50:50 mix of 103 and 104 amino acid iso-
forms). The generic names ‘artemin’ and ‘neublastin’ cover
all forms of the protein (104, 113, 125 and full length) and
do not accurately describe BG00010. All other drug/target
nomenclature is consistent with the British Journal of
Pharmacology’s ‘Guide to Receptors and Channels’ [15].
Since BG000010 is intravenously administered, less fre-
quent dosing is preferable, and unpublished non-clinical
data suggested that less frequent administration with
higher doses and more frequent administration at lower
doses could be explored clinically, providing the rationale
for studying two dosing schedules. In Part I (Cohorts
A–D), patients received BG00010 (50, 150, 400 or
800 μg kg1) or placebo once weekly for 3 weeks. In Part
II (Cohorts E–G), patients received BG00010 or placebo
dosed every 48 h. The starting dose in Part II was to be
no more than 400 μg kg1 and at least one dose level
below the maximum tolerated dose (MTD) established
with the once-weekly schedule.
Patients were enrolled sequentially, cohort by cohort. For
each cohort, patients were randomized (three patients to
BG00010 and one to placebo) to receive three IV administra-
tions of study treatment. Following the completion of
treatment for each cohort, the Data Safety Review Committee
(DSRC) determined if it was appropriate to escalate to the
next planned dose level. If none of the three BG00010-
treated patients within a cohort experienced a treatment-
related dose-limiting toxicity (DLT; defined as all
BG00010-related serious AEs [SAEs] and BG00010-related
AEs coded as severe by the Principal Investigator), dose
escalation proceeded to the next cohort. If one of three
BG00010-treated patients experienced a treatment-related
DLT, three additional patients were to be enrolled at that
dose level and escalation was to continue if there were no
other DLTs among the additional BG00010-treated patients.
If two or more BG00010-treated patients experienced the
same or a similar treatment-related DLT, dosing was to stop,
and the previous dose level was to be considered the MTD.
If patients experienced DLTs that were not the same or
similar in nature, the cohort could be expanded or dosing
stopped, as recommended by the DSRC.Study assessments
The primary objective of the study was to evaluate the PK and
safety of three IV injections of BG00010 in two fixed dosing
schedules: weekly and as frequently as every 48 h (no more
than three times in 1 week). Secondary objectives were to ex-
plore the potential of BG00010 to reduce pain following
multiple-dose administration (as measured by a numerical
rating scale (NRS) and the SF-MPQ VAS) and to explore the
repeated-dose immunogenicity of BG00010 (as measured by
the incidence of anti-BG00010 antibodies).
In Parts I and II of the study, blood samples for PK anal-
ysis were taken: 30 min pre-dose and then 15 min and 1,
2.5, 4, 6, 9, 12, 18, 24 and 48 h following the first dose of
BG00010; 30 min pre-dose and then 15 min and 4, 24
and 48 h following the second dose of BG00010; 30 min
pre-dose and then 15 min and 1, 2.5, 4, 6, 9, 12, 18, 24,
48, 72 and 120 h following the third dose of BG00010.
The concentration of BG00010 in serum was determined
using a chemiluminescent enzyme-linked immunosorbent
assay (quantification range 0.1–10 ng/ml) based on the
binding of BG00010 to immobilized anti-BG00010 anti-
body (P3B3) using streptavidin conjugated with horseradish
peroxidase, which upon addition of luminol substrate
produced a chemiluminescent signal. At the lower limit
of quantification, assay precision and bias were 12.5%
and 13.6% respectively. Assay performance was fully
validated in accordance with regulatory guidance and in-
dustry best practices.
Safety assessments included recording AEs and SAEs, mea-
surements of haematology, clinical chemistry, and urinalysis
variables; vital signs; physical examinations; neurologic
examinations; electrocardiograms (ECGs); numerical pain
rating assessments; and longitudinal assessment of quantita-
tive sensory testing (QST) in the unaffected leg (vibratory,
cool thermal and heat pain). For vibratory measurements, a
Rydel-Seiffer vibratory tuning fork was used. The Rydel-Seiffer
vibratory tuning fork is an instrument that can determine the
vibration extinction threshold. The tuning fork was set to a
vibratory frequency of 64 Hz and then placed on the subject’s
skin. The vibration threshold was the point where the vibra-
tion was no longer perceived by the subject [16].
Measurements were performed in triplicate on the medial
malleolus. Cold and heat stimuli were applied with a
thermode device (TSA-II – NeuroSensory Analyzer, Medoc)
which gradually increased or decreased in temperature. The
thermode was applied to the inner aspect of the calf muscle
of the unaffected leg. Cold sensation, cold pain threshold,
heat pain threshold and heat pain tolerance were assessed.
For the QST, the change from baseline was noted if there
was a change of ≥2 standard deviations (SD) of laboratory nor-
mative data from the baseline measurement. As BG00010 is
involved in nerve growth, intra-epidermal nerve fibre density
(IENFD) was measured as a safety precaution. A punch biopsy
of the distal part (10 cm proximal to the lateral malleolus) of
the unaffected leg was performed twice (on the same leg
within 1 h) to minimize patient variance.
The presence of anti-BG00010 antibodies was determined
using a tiered assay approach involving a screening assay and
a confirmation assay, followed by titration of positive
samples. The presence of anti-BG00010 antibodies in human
serum was determined using an electrochemiluminescentBr J Clin Pharmacol (2016) •• ••–•• 3
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antibodies were further evaluated in a neutralizing antibody
assay that measured the ability of BG00010 to bind to and
activate the extracellular GFRα3 receptor. Assay performance
was fully validated in accordance with regulatory guidance
and industry best practices.
Plasma and serum samples were also drawn to explore
potential pharmacodynamic markers: Substance P, chemo-
kine receptor 2 (CCR2) and norepinephrine.
The efficacy assessments were an 11-point NRS assess-
ment (general sciatic pain, back pain and leg pain) and pain
as measured by the VAS of the SF-MPQ. Nociceptive testing
was performed as exploratory assessment. Electrical, mechan-
ical and cold pressor tests were performed to assess pain
detection and pain tolerance thresholds.Statistical analyses
This was an exploratory study; therefore, the sample size was
not based on statistical considerations. PK parameters were
calculated using noncompartmental methods, and summary
statistics for each PK parameter were calculated by dose.
The mean concentration values for each dose group were
plotted over time, and dose proportionality was assessed.
Calculations were performed using WinNonlin Phoenix
version 6.2 (Certara, Princeton, USA).
All patients who were randomized were analysed. AEs
were coded using the Medical Dictionary for Regulatory
Activities (MedDRA) version 15.0. The incidences of AEs, SAEs
and development of antibodies to BG00010, as well as
changes in safety parameters, were summarized by study dose
and compared with placebo. Placebo patients were pooled
together separately in Parts I and II.
The efficacy analysis population was defined as all
patients who received study treatment and had pain data
collected post-dose. Changes in the 11-point NRS and VAS
of the SF-MPQwere summarized by study dose and compared
with placebo.Figure 1
Mean (+ SD) serum BG00010 concentration vs. time by cohort in
Part I (A: ( ) 50 μg kg1 (n = 3), ( ) 150 μg kg1 (n = 3), ( )
400 μg kg1 (n = 3), ( ) 800 μg kg1 (n = 3)) and Part II (B: ( )
400 μg kg1 (n = 3), ( ) 600 μg kg1 (n = 3), ( ) 1200 μg kg1
(n = 3))Results
Study population
Twenty-eight patients were randomized (see Figure S1
for study flowchart); 16 in Part I of the study to BG00010
(50, 150, 400 or 800 μg kg1 once weekly) or placebo and 12
in Part II to BG00010 (400, 600 or 1200 μg kg1 up to every
48 h and nomore than 3 times in 1 week) or placebo. The first
dose of study treatment was administered on 25 July 2011,
and the last study visit was on 20 September 2012.
In Part I, 10 patients (63%) were women; in Part II,
9 patients (75%) were women. The mean age was 53.5 years
(range 33–75 years) in Part I and 51.4 years (range 19–74
years) in Part II. The majority of patients were white
(22 [79%]). Concomitant medications were taken by
15/16 (94%) patients in Part I and 9/12 (75%) patients in
Part II. The most frequent concomitant medication was
paracetamol (9/15 [60%] patients in Part I and 3/9 [33%]
patients in Part II).4 Br J Clin Pharmacol (2016) •• ••–••Pharmacokinetics
In all study cohorts, the BG00010 concentration–time data
indicated relatively low inter-patient variability in the time
course of BG00010 serum exposure. Serum BG00010
concentrations over time are shown in Figure 1. There was a
dose-dependent increase in serum exposure from 150 to
1200 μg kg1, but the increase was less than dose-
proportional. The log-linear BG00010 concentration vs. time
course at all dose levels showed a distinct multiphasic dispo-
sition in which peak concentrations dropped more than ten-
fold in the first 2–3 h post-dose and declined more slowly
thereafter. There was no trend toward increasing or decreas-
ing clearance (CL) or steady-state volume of distribution
(Vss) across the body weight range tested (62.6–106.4 kg).
A summary of the PK parameters for Parts I and II of the
study is given in Table 1. In Part I of the study, the area under
the concentration–time curve from time zero to infinity (AUCinf)
increased approximately in proportion to dose from 0 to
400 μg kg1 and somewhat less than dose proportionally from
400 to 800 μg kg1 (Table 1). There was no difference in AUCinf
between the first (Dose 1) and third (Dose 3) dose within each
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P. Okkerse et al.maximal plasma concentration (Cmax) also increased with
BG00010 dose, but reached a plateau from 400 to 800 μg kg1
(Table 1). Reaching a plateau in Cmax between these dose
levels was expected due to increasing IV infusion time. CL
was relatively constant over the dose range tested for Co-
horts A to D. Mean Vss for all cohorts increased as a func-
tion of dose. Estimation of Vss at the lower dose levels
(Cohorts A and B) was influenced by the limited range of
concentration–time data and therefore produced underesti-
mates of the true volume. At the higher dose levels (Cohorts
C and D), mean Vss fell within a tighter range (Table 1).
In Part II of the study, the increase in AUC during a dosing
interval (0–48 h) at steady state (AUCtau) was less than pro-
portional to dose, and AUCtau for Dose 3 was higher than
that for Dose 1 in all cohorts, indicating some degree of ac-
cumulation (Table 1). Cmax for Cohorts E–G increased with
dose, but formed a similar plateau as observed in Cohorts
A–D. There was little or no BG00010 accumulation with a
168 h dose interval in Cohorts A to D and some accumula-
tion (29–55%) with a 48 h dose interval in Cohorts E–G,
indicating an effective half-life (t½ (eff)) for BG00010
between 30 and 60 h.Figure 2
Adverse-event overview in Part I (A) and Part II (B) for pruritus events. *Patie
related events
6 Br J Clin Pharmacol (2016) •• ••–••Safety
All patients experienced AEs. The most frequently reported
AEs reported by patients receiving BG00010 were headache
(10 BG00010-treated patients [83%] vs. 3 placebo-treated pa-
tients [75%] in Part I and 6 [67%] vs. 1 [33%] in Part II), feeling
hot (6 [50%] vs. 0 in Part I and 9 [100%] vs. 0 in Part II), gen-
eralized pruritus (8 [67%] vs. 1 [25%] in Part I and 3 [33%] vs. 0
in Part II) and pruritus (5 [42%] vs. 2 [50%] in Part I and
6 [67%] vs. 0 in Part II). The majority of AEs were mild; no
severe AEs, SAEs or AEs leading to discontinuation were
observed. There was no indication for increased reporting of
AEs with increasing BG00010 dose or increasing frequency
of BG00010 dosing.
An overview of pruritus-related AEs is shown in Figure 2.
All AEs pertaining to pruritus were considered related to study
treatment and resolved by the end of the follow-up period.
Pruritus that lasted >28 days was reported in five patients:
this was mild in severity and no modification of study treat-
ment was required in any of the five patients. One patient re-
ported a generalized rash during the study. The patient was in
the BG00010 50 μg kg1 group and the AE was mild in sever-
ity and lasted 5 days. One patient in the BG00010 150 μg kg1nt received placebo. Severity: 1 = mild; 2 = moderate. ( ) Pruritus-
PK/PD of the neurotrophic factor BG00010 in patients with sciaticagroup had a temperature-related AE of moderate severity
(feeling hot) that lasted 3 days. The same event occurred after
the second and third dose, but were of mild severity. Five pa-
tients in Part I experienced mild temperature-related AEs that
lasted between 1 and 5 days. Nine patients in Part II experi-
enced mild temperature-related AEs with duration of 1–
2 days. No clear trends in response to multiple doses of
BG00010 were observed in blood levels of Substance P or
CCR2 in Parts I or II of the study.
In Parts I and II, the most frequent concomitant medication
was paracetamol. Use of concomitant medications as permitted
by the protocol was not expected to affect study results.
No clinically significant changes were found in vital signs,
ECG, IENFD, QST or safety laboratory tests. Although some pa-
tients, at some points, had QST values outside the normal
range, none of these changes were determined to be a rea-
son for concern. Observed changes were considered within
the expected variability of QST assessments (data not
shown). The change in IENFD from baseline is shown in
Figure 3. No trends in IENFD data were observed and no
clear dose effect was documented in Parts I or II of the
study. There was no correlation between changes in IENFD
and clinical findings, and the changes that were seen were
considered not clinically significant.
The only case of anti-BG00010 antibodies detected in the
study was in a patient receiving placebo. This was a false
positive result on Day 20; results were negative on Day 43.
No neutralizing antibodies were detected.Pharmacodynamics
Change frombaseline inNRS over time is shown in Figure 4.On
the NRS in Part I, there was little differentiation between
placebo-treated patients and patients treated with BG00010 50
or 150 μg kg1 in mean change in general sciatica pain from
baseline. There was more differentiation for patients treatedFigure 3
Median (± range) change in IENFD from baseline by treatment and visit in P
3, ( ) 56 days post Dose 3). ENF, epidermal nerve fibre; IENFD, intra-epidewith BG00010 400 or 800 μg kg1, observed particularly after
Dose 2. After Dose 2, patients receiving BG00010 ≥ 400 μg kg1
reported greater reductions in general sciatica pain and these
reductions weremaintained after Dose 3. However, overall there
was substantial variability in theNRS data. In Part II of the study,
mean changes from baseline among placebo-treated patients
remained within a lower range relative to that observed for
placebo treatment in Part I and the treatment response was far
more evident with the Part II dosing regimen. Results for leg
pain and back pain, as measured by the NRS, were similar to
those seen for general pain.
In Part I, BG00010 800 μg kg1 resulted in the greatestmean
(SD) decrease from baseline in VAS score (34 [14] mm at
Week 6). The greatest mean decrease from baseline for
placebo-treated patients was seen at Week 10 (20.67
[31.63] mm). For the other doses tested in Part I, no pain re-
duction was seen compared with placebo-treated patients.
In Part II of the study, the greatest mean decrease from
baseline was seen 56 days after Dose 3 in the 600 μg kg1 dose
group (mean [SD] of33.33 [33.38] mm vs.3.67 [20.03] mm
with placebo). A trend in pain reduction from baseline as
measured by the VAS of the SF-MPQ was seen in the
BG00010 600 and 1200 μg kg1 dose groups compared with
placebo. No notable trends were seen in the nociceptive test-
ing data (Table S1a-f; Figure S2).Discussion
Overall, BG00010 dosed weekly or every 48 h demonstrated
dose-dependent PK in this ascending-dose study in patients
with sciatica. There were no DLTs, the MTD was not
identified, and BG00010 administration appeared to lead to
a reduction in back pain and leg pain in some patients.
When administered as multiple doses by IV infusion at
48- or 168-hour dose intervals, serum BG00010 exposureart I (A: ( ) Week 6, ( ) Week 10) and Part II (B: ( ) 28 days post Dose
rmal nerve fibre density
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Figure 4
Mean (± SE) NRS pain general assessment change from baseline for Part I (A: ( ) Placebo (n = 4), ( ) 50 μg kg1 (n = 3), ( ) 150 μg kg1
(n = 3), ( ) 400 μg kg1 (n = 3), ( ) 800 μg kg1 (n = 3)) and Part II (B: ( ) Placebo (n = 3), ( ) 400 μg kg1 (n = 3), ( ) 600 μg kg1
(n = 3), ( ) 1200 μg kg1 (n = 3)). NRS, numerical rating scale
P. Okkerse et al.increased in a dose-dependent, but less than dose-
proportional, manner with relatively low variability within
dose cohorts. At all dose levels, the log-linear BG00010
concentration–time course showed a distinctmultiphasic dispo-
sition in which peak concentrations droppedmore than tenfold
in the first 2–3 h after administration and then declined more
slowly over the following days with a t½ that generally fell be-
tween 40 and 60 h. There was no accumulation of BG00010
when dosed at a 168-hour interval, but there was some accumu-
lation when dosed every 48 h (accumulation ratio: 29–55%),
suggesting a t½ (eff) for BG00010 of approximately 30–60 h.
The PK results in the current study are consistent with those ob-
served in the previous single ascending-dose study with
BG00010 [13].
All patients experienced at least one AE during the study
and AEs were more frequently reported in patients receiving
BG00010 versus placebo. There was no clear increase in the
incidence of the most frequent AEs for the higher- versus
lower-dose cohorts or in the cohorts where BG00010 was ad-
ministered three times during 1 week versus once weekly for
3 weeks. One of the most frequently reported AEs in this8 Br J Clin Pharmacol (2016) •• ••–••study was mild or moderate pruritus, starting approximately
1–3 days following administration of Dose 1. The exactmech-
anism of the pruritus is not known, but pruritus was also seen
in a single ascending-dose study where it was more common
with higher BG00010 doses (≥100 μg kg1) [13]. In our study,
with weekly dosing, patients who received the highest
BG00010 dose (800 μg kg1) experienced pruritus AEs of lon-
ger duration than patients in the other treatment groups.
However, in Part II of the study, when BG00010 was dosed ev-
ery 48 h, there was no clear indication of pruritus AEs having
a longer duration with increasing BG00010 dose. The single
case of anti-BG00010 antibodies being detected in a patient
receiving placebo was a false positive result, not unexpected
as the assay cut point incorporates a 5% false positive rate.
The effects of BG00010 on neuropathic pain behaviour
have been studied extensively in rats. Three rat models of
neuropathic pain have been examined: spinal nerve ligation
[3], chronic constriction injury of the sciatic nerve [17] and
distal root crush [18]. In these models, BG00010 substantially
attenuated neuropathic pain behaviour. Exposure to
BG00010 at single doses of 400 or 800 μg kg1 in humans
PK/PD of the neurotrophic factor BG00010 in patients with sciaticawas comparable to exposure in rats at doses that have shown
efficacy in these nonclinical pain models. In this study, based
on the NRS and VAS of the SF-MPQ, the Part II multiple-dose
BG00010 regimen resulted in greater pain reduction versus
placebo and the lower-dose regimens, although a clear dose–
response relationship was not seen. These limited data sug-
gest that BG00010may benefit patients with sciatica and that
further development of this compound for the treatment of
neuropathic pain is warranted.
No formal sample size calculation was performed for the
efficacy endpoints; therefore, owing to the small sample size
of each cohort, no final conclusions can be made about the
efficacy of BG00010 at this point. Nociceptive testing was
included as an exploratory measure. With only three subjects
per dose group, large variability was observed in baseline
values of the different nociceptive tasks. No effects of
BG00010 on evoked pain were observed. Likely the group size
was too small to detect clear effects on evoked pain.
A recent review [19] concluded that available evidence does
not clearly show favourable effects with nonsteroidal anti-
inflammatory drugs, corticosteroids, antidepressants or opioid
analgesics for the treatment of sciatica. There has, however,
been significant progress over the last 20 years in the under-
standing of the biology of pain sensory neurons, and the discov-
ery that neurotrophic factors play an important role in
neuropathic pain has provided several new therapeutic targets.
Although sciatica probably has mixed neuropathic and
nociceptive/inflammatory components, neurotrophic factors
such as the GDNF family of ligands may address certain aspects
of the underlying causes of neuropathic pain.
In conclusion, PK results were consistent with those ob-
served in previous research. There were no DLTs and a MTD
was not identified. These data from a small sample suggest
that further evaluation of BG00010 in patients with sciatica
is warranted. Additionally, a phase II study in patients with
radiculopathy has recently been completed.Competing Interests
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